Related Experiment Videos

Who should receive myeloablative therapy for lymphoma?

T Andrew Lister¹

¹Department of Medical Oncology, St. Bartholomew's Hospital, London.

The New England Journal of Medicine

|March 27, 2004

Summary

No abstract available in PubMed .

Related Concept Videos

Articles linked to this work by shared authors, journal, and citation graph.

Recurrent mTORC1-activating RRAGC mutations in follicular lymphoma.

Nature genetics·2015

Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2014

Integrated genomic analysis identifies recurrent mutations and evolution patterns driving the initiation and progression of follicular lymphoma.

Nature genetics·2013

Fertility and sexual function in long-term survivors of haematological malignancy: using patient-reported outcome measures to assess a neglected area of need in the late effects clinic.

British journal of haematology·2013

EZH2 mutations are frequent and represent an early event in follicular lymphoma.

Blood·2013

Myeloablative chemotherapy for chemo-sensitive recurrent follicular lymphoma: potential benefit in second relapse.

Haematologica·2012

See all related articles